Overview

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2020-05-11
Target enrollment:
Participant gender:
Summary
The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.
Phase:
Phase 1
Details
Lead Sponsor:
Institut de Recherches Internationales Servier
Collaborators:
ADIR Association
ADIR, a Servier Group company